Degree of African ancestry may influence gene expression levels

January 26, 2020 – Common belief holds that differences in genes (i.e., allelic variants) in combination with differing frequencies of such allelic variants in populations of different ethnic background may explain the differences in the frequency and/or severity of overt diseases in different ethnic groups and/or populations.

Basically, the study here asked if the shade of “gray” meaning the skin tones in African Americans from very light to rather dark matter when it comes to the level of expression of certain genes? The answer seems to be yes. Thus, there were at least 28 genes found whose expression (i.e., atteined mRNA level) varied with the proportion of African ancestry. These genes were linked to 220 diseases or clinical outcomes such as coronary heart disease and triglyceride levels. Some of the identified genes that vary with African ancestry are related to drug metabolism (CYP2C19), renal disease (APOL1), and an important target for cancer therapy (VEGF).

The exact molecular mechanisms for the variations in gene expression in are not yet clear. One contributing factor might be the phenomenon of transcriptional bursting where in diploid cells, where each single gene is represented by two allelic copies (which need not be identical, but may be allelic variants) and where one of the two alleles may be expressed preferentially and to much higher degrees than its allelic counterpart.

Such mechanisms may be very important in populations like African Americans and other admixed populations like Latinos, but of  course of “Caucasians” and Asian populations and lead to wide variability in both responses to drug treatments and genetic predisposition to disease. Unfortunately these types of data are sorely missing in most of the public databases so far.

See this short sequence on genetics of populations:

Print Friendly, PDF & Email

Tags: , , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion

Comment

No comments yet

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • How genetic variation gives rise to differences in mathematical ability October 22, 2020
    DNA variation in a gene called ROBO1 is associated with early anatomical differences in a brain region that plays a key role in quantity representation, potentially explaining how genetic variability might shape mathematical performance in children, according to a study published October 22nd in the open-access journal PLOS Biology by Michael Skeide of the Max […]
  • High-quality cat genome helps identify novel cause of dwarfism October 22, 2020
    A new and improved cat genome developed by the feline research teams at the University of Missouri and Texas A&M University has already proven to be a valuable tool for feline biomedical research by helping to confirm existing gene variants and new candidate genes underlying diseases in cats. The new findings are published October 22nd […]
  • Multiple sclerosis as the flip side of immune fitness October 22, 2020
    About half of the people with multiple sclerosis have the HLA-DR15 gene variant. A study led by the University of Zurich has now shown how this genetic predisposition contributes to the development of the autoimmune disease multiple sclerosis in combination with environmental factors. The decisive factor is the shaping of a repertoire of immune cells […]
  • Scientists use gene therapy and a novel light-sensing protein to restore vision in mice October 22, 2020
    A newly developed light-sensing protein called the MCO1 opsin restores vision in blind mice when attached to retina bipolar cells using gene therapy. The National Eye Institute, part of the National Institutes of Health, provided a Small Business Innovation Research grant to Nanoscope, LLC for development of MCO1. The company is planning a U.S. clinical […]
  • Diagnostic, therapeutic advance for rare neurodegenerative disorder October 21, 2020
    Mayo Clinic researchers, along with national and global collaborators, have developed a potential test for Machado-Joseph disease, or spinocerebellar ataxia type 3 (SCA3)—a disease that has no cure. They also have clarified the role of a gene target associated with the disease.
Top